Jevtana

Jevtana

Manufacturer:

Sanofi-Aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Cabazitaxel
Indications/Uses
In combination w/ prednisone for hormone-refractory metastatic prostate cancer previously treated w/ a docetaxel-containing treatment regimen.
Dosage/Direction for Use
Recommended dose: 25 mg/m2 as a 1-hr IV infusion every 3 wk w/ oral prednisone 10 mg daily.
Contraindications
Hypersensitivity to cabazitaxel & polysorbate 80; neutrophil count <1,500/mm3; hepatic impairment (bilirubin ≥1x ULN or AST &/or ALT ≥1.5x ULN); yellow fever vaccinee.
Special Precautions
Hypersensitivity reactions; high-risk of neutropenia eg, patients w/ poor performance status, previous febrile neutropenia episodes, extensive prior radiation ports, poor nutritional status, or other serious comorbidities; nausea, vomiting, diarrhea & dehydration; peripheral neuropathy (sensory & motor), cardiac arrhythmia, alcoholics, renal failure, severe or end-stage renal disease, epileptic patients, anemia. May affect ability to drive or operate machinery. Elderly ≥65 yr. Pregnancy & lactation.
Adverse Reactions
Anaemia, leukopenia, neutropenia, thrombocytopenia; anorexia; dysgeusia; dyspnea, cough; diarrhea, nausea, vomiting, constipation, abdominal pain; alopecia; back pain, arthralgia; haematuria; fatigue, asthenia, pyrexia, peripheral neuropathy.
Drug Interactions
CYP3A inducers & inhibitors, live or live-attenuated vaccines, St. John's wort, OATP1B1 substrates.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CD04 - cabazitaxel ; Belongs to the class of taxanes from plant alkaloids and other natural products. Used in the treatment of cancer.
Presentation/Packing
Form
Jevtana soln for infusion 60 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in